Alzamend Neuro (NASDAQ:ALZN) Price Target Lowered to $32.00 at Ascendiant Capital Markets

Alzamend Neuro (NASDAQ:ALZN) had its price objective lowered by Ascendiant Capital Markets from $35.00 to $32.00 in a research report report published on Monday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Alzamend Neuro Trading Down 4.7 %

NASDAQ:ALZN opened at $1.23 on Monday. The firm has a 50 day moving average of $1.44 and a 200-day moving average of $2.59. Alzamend Neuro has a 1 year low of $1.06 and a 1 year high of $15.06.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.